Mesoblast Limited
MESO evidence brief
What we can confirm
- Market Cap:
- $2.01B
What it means
What to watch
Prepared research question
What matters most for MESO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MESO
Mesoblast Limited is an Australian biotechnology company developing allogeneic stromal cell therapies for inflammatory and degenerative diseases, with one approved product (Ryoncil) and several late-stage clinical programs.
Key risk: Continued net losses
Market Cap
$2.01B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 12 clinical trials for Mesoblast Limited.
Mesoblast Limited is an Australian biotechnology company developing allogeneic stromal cell therapies for inflammatory and degenerative diseases, with one approved product (Ryoncil) and several late-stage clinical programs.
- Mesoblast has one FDA-approved product, Ryoncil (remestemcel-L), for pediatric steroid-refractory acute graft-versus-host disease, commercialized since March 2025 [sec · filed 2026-08-27].
- The company reported a net loss of $57.5 million for the fiscal year ended June 30, 2026 [sec · filed 2026-08-27].
- As of December 31, 2025, Mesoblast held total cash reserves of $130.0 million [sec · filed 2026-02-27].
- In July 2026, Mesoblast achieved the target of at least 300 patients treated in the pivotal Phase 3 trial of rexlemestrocel-L for chronic lower back pain [sec · filed 2026-08-27].
- Mesoblast drew down US$50.0 million from a five-year facility in 2026 to retire a higher-cost debt facility [sec · filed 2026-08-27].
What works
- Mesoblast has a commercially approved product, Ryoncil, generating revenue in the U.S. market, providing a foundation for ongoing operations [sec · filed 2026-08-27].
- The company achieved the target enrollment of at least 300 patients in the pivotal Phase 3 trial for rexlemestrocel-L in chronic lower back pain, a key milestone toward potential BLA filing [sec · filed 2026-08-27].
- Mesoblast reduced its debt burden by drawing down a new facility to retire higher-cost debt, improving its financial structure [sec · filed 2026-08-27].
- The company has multiple late-stage programs (chronic heart failure, chronic lower back pain, adult SR-aGvHD) and partnerships in Japan, Europe, and China, diversifying its pipeline [sec · filed 2026-02-27].
What to weigh
- Mesoblast reported a net loss of $57.5 million for fiscal year 2026 and expects to continue incurring significant losses for the foreseeable future [sec · filed 2026-08-27].
- The company's near-term success is heavily dependent on sales of Ryoncil, which faces market acceptance, label expansion, and competitive risks [sec · filed 2026-08-27].
- Mesoblast may need additional funding to sustain operations and development, and any fundraising could dilute existing shareholders or impose unfavorable terms [sec · filed 2026-02-27].
- The company has no assurance of ever achieving or maintaining profitability, and its expenses could increase if regulators require additional studies [sec · filed 2026-08-27].
From the filings
Quoted directly from source documents.
Net loss for fiscal year 2026
“net loss for the year ended June 30, 2026 was $57.5 million.”
SEC filings · August 27, 2026
Cash reserves as of December 31, 2025
“As of December 31, 2025, we held total cash reserves of $130.0 million.”
SEC filings · February 27, 2026
Phase 3 CLBP trial target achieved
“Achieved the target of at least 300 patients treated in the pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for CLBP associated with degenerative disc disease.”
SEC filings · August 27, 2026
Risks & what to watch (4)›
Key risks
- Continued net losses — Net loss of $57.5M in FY2026; expects significant losses for the foreseeable future [sec · filed 2026-08-27].
- Single-product revenue dependence — Business sustainability largely dependent on Ryoncil sales until next product approval [sec · filed 2026-08-27].
- Regulatory and clinical costs — Expenses could increase if FDA or other agencies require additional studies beyond current plans [sec · filed 2025-08-29].
- Funding and dilution risk — May need additional funding; fundraising could dilute shareholders or impose unfavorable terms [sec · filed 2026-02-27].
What to watch
- FDA decision on the BLA for rexlemestrocel-L in chronic lower back pain, following the completed Phase 3 trial [sec · filed 2026-08-27].
- Sales trajectory and market adoption of Ryoncil in the U.S., as it is critical to near-term revenue [sec · filed 2026-08-27].
- Progress of the pivotal trial for Ryoncil in adults with SR-aGvHD, in collaboration with the NIH-funded BMT CTN [sec · filed 2026-02-27].
- Potential label expansion of Ryoncil into additional indications and jurisdictions [sec · filed 2026-08-27].
Sources: SEC filings · Generated September 27, 2026 · How we verify sources →
Run Mesoblast Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mesoblast Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
68
Total value held
$49.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 630,855 | $9.7M |
| morgan stanley | 514,431 | $7.9M |
| goldman sachs group inc | 397,215 | $6.1M |
| susquehanna international group, llp | 386,472 | $5.9M |
| ubs group ag | 132,573 | $2.0M |
| bank of america corp /de/ | 100,004 | $1.5M |
| jane street group, llc | 98,786 | $1.5M |
| penbrook management llc | 87,075 | $1.3M |
| citadel advisors llc | 85,959 | $1.3M |
| group one trading llc | 83,915 | $1.3M |
Showing top 10 of 68 institutional holders of Mesoblast Limited. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 3.3%
- Days to cover
- 10.4
- Shares short
- 3,049,603
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MESO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mesoblast Limited?
Mesoblast Limited is an Australian biotechnology company developing allogeneic stromal cell therapies for inflammatory and degenerative diseases, with one approved product (Ryoncil) and several late-stage clinical programs.
Who is the CEO of Mesoblast Limited?
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) is the chief executive officer of Mesoblast Limited (MESO).
Where is Mesoblast Limited headquartered?
Mesoblast Limited (MESO) is headquartered in Melbourne, VIC, Australia.
What therapeutic areas does Mesoblast Limited focus on?
Mesoblast Limited develops therapies across Oncology, Gene Therapy, Immunology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.